1. Academic Validation
  2. A Theileria annulata parasite with a single mutation, methionine 128 to isoleucine (M128I), in cytochrome B is resistant to buparvaquone

A Theileria annulata parasite with a single mutation, methionine 128 to isoleucine (M128I), in cytochrome B is resistant to buparvaquone

  • PLoS One. 2024 Apr 16;19(4):e0299002. doi: 10.1371/journal.pone.0299002.
Shahin Tajeri 1 2 Debasish Chattopadhyay 3 Gordon Langsley 4 5 Ard M Nijhof 1 2
Affiliations

Affiliations

  • 1 Institute for Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
  • 2 Veterinary Centre for Resistance Research, Freie Universität Berlin, Berlin, Germany.
  • 3 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
  • 4 Inserm U1016-CNRS UMR8104, Institut Cochin, Paris, France.
  • 5 Laboratoire de Biologie Comparative des Apicomplexes, Faculté de Médecine, Université Paris Descartes-Sorbonne Paris Cité, Paris, France.
Abstract

Tropical theileriosis is a fatal leukemic-like disease of cattle caused by the tick-transmitted protozoan Parasite Theileria annulata. The economics of cattle meat and milk production is severely affected by theileriosis in endemic areas. The hydroxynaphtoquinone buparvaquone (BPQ) is the only available drug currently used to treat clinical theileriosis, whilst BPQ resistance is emerging and spreading in endemic areas. Here, we chronically exposed T. annulata-transformed macrophages in vitro to BPQ and monitored the emergence of drug-resistant parasites. Surviving parasites revealed a significant increase in BPQ IC50 compared to the wild type parasites. Drug resistant parasites from two independent cloned lines had an identical single mutation, M128I, in the gene coding for T. annulata cytochrome B (Tacytb). This in vitro generated mutation has not been reported in resistant field isolates previously, but is reminiscent of the methionine to isoleucine mutation in atovaquone-resistant Plasmodium and Babesia. The M128I mutation did not appear to exert any deleterious effect on Parasite fitness (proliferation and differentiation to merozoites). To gain insight into whether drug-resistance could have resulted from altered drug binding to TaCytB we generated in silico a 3D-model of wild type TaCytB and docked BPQ to the predicted 3D-structure. Potential binding sites cluster in four areas of the protein structure including the Q01 site. The bound drug in the Q01 site is expected to pack against an alpha helix, which included M128, suggesting that the change in amino acid in this position may alter drug-binding. The in vitro generated BPQ resistant T. annulata is a useful tool to determine the contribution of the various predicted docking sites to BPQ resistance and will also allow testing novel drugs against theileriosis for their potential to overcome BPQ resistance.

Figures
Products